iomeprol has been researched along with fluorodeoxyglucose f18 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| An, YS; Hwang, SC; Oh, YJ; Sheen, SS; Yoon, JK | 1 |
| Domeki, Y; Fukasawa, I; Inaba, N; Kaji, Y; Kitajima, K; Murakami, K; Suganuma, N; Sugimura, K; Yamasaki, E | 1 |
| Bakhshi, S; Dhawan, D; Kumar, R; Malhotra, A; Radhakrishnan, V; Sharma, P; Thulkar, S; Vishnubhatla, S | 1 |
| Domínguez Ferreras, E; García Vicente, AM; Jiménez Aragón, F; Molino Trinidad, C; Pineda Pineda, MD; Poblete García, VM; Sánchez Pérez, V; Soriano Castrejón, Á; Villa Guzmán, JC | 1 |
| Blickman, JG; Maffione, AM; Rampin, L; Rubello, D | 1 |
| Handra-Luca, A | 1 |
1 trial(s) available for iomeprol and fluorodeoxyglucose f18
| Article | Year |
|---|---|
Response assessment of colorectal liver metastases with contrast enhanced CT/18F-FDG PET.
Topics: Adult; Aged; Colorectal Neoplasms; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Iopamidol; Liver Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Spain; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
5 other study(ies) available for iomeprol and fluorodeoxyglucose f18
| Article | Year |
|---|---|
Nonionic intravenous contrast agent does not cause clinically significant artifacts to 18F-FDG PET/CT in patients with lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Artifacts; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Iopamidol; Lung; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Subtraction Technique; Tomography, X-Ray Computed | 2007 |
Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.
Topics: Adult; Aged; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Iopamidol; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Systems Integration; Tomography, X-Ray Computed | 2008 |
Pediatric nonlymphoblastic non-Hodgkin lymphoma: baseline, interim, and posttreatment PET/CT versus contrast-enhanced CT for evaluation--a prospective study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Contrast Media; Diatrizoate; Female; Fluorodeoxyglucose F18; Humans; Iopamidol; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Invited editorial: Response to therapy assessment of colorectal liver metastasis.
Topics: Adult; Aged; Colorectal Neoplasms; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Iopamidol; Liver Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Spain; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Xanthomatous Interstitial Pneumopathy: Chemotherapy- or Contrast Substance Related Change?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Fluorodeoxyglucose F18; Humans; Iopamidol; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Pneumonectomy; Positron-Emission Tomography; Xanthomatosis | 2020 |